STOCK TITAN

Organogenesis Hldgs Inc - ORGO STOCK NEWS

Welcome to our dedicated page for Organogenesis Hldgs news (Ticker: ORGO), a resource for investors and traders seeking the latest updates and insights on Organogenesis Hldgs stock.

Overview

Organogenesis Holdings Inc (ORGO) is a global, innovative force in the field of regenerative medicine, specializing in the development, manufacture, and commercialization of bioactive and acellular biomaterials. With a robust portfolio that spans advanced wound care, surgical biologics, and targeted sports medicine solutions, the company addresses complex repair and regenerative needs across various patient segments. By integrating advanced technologies and scientific research, Organogenesis delivers products that enhance tissue regeneration, promote wound healing, and provide surgical support in orthopedics and spine applications.

Core Business and Product Portfolio

At the heart of Organogenesis Holdings Inc is its commitment to regenerative medicine. The company’s dual-segment business model emphasizes a comprehensive range of products designed for advanced wound care and surgical applications. Among its offerings are bioactive skin substitutes, acellular matrices, and innovative surgical barriers that provide clinicians with non-surgical and surgical options for managing complex wounds and soft tissue injuries. The scientifically backed formulation of these products underscores a deep understanding of tissue repair mechanisms and exemplifies the integration of clinical research with manufacturing excellence.

Market Position and Industry Expertise

Operating within a highly specialized niche in healthcare, Organogenesis stands as a testament to applied research and technical innovation in regenerative medicine. The company’s products are designed to address longstanding clinical needs, offering alternatives where traditional therapies have limitations. With significant emphasis on data-driven outcomes and safety profiles, their approach reassures stakeholders and medical professionals alike. Their market presence is reinforced by the clinical validation of key product categories, strategic manufacturing locations, and a commitment to scalable, high-quality production practices.

Regulatory and Clinical Integration

Organogenesis navigates a complex regulatory landscape that governs the development of medical products. Their adherence to stringent clinical protocols and transparent reporting standards reflects in the rigorous evaluation of their products in clinical trials. This commitment not only bolsters trust within the scientific community but also demonstrates a sustainable model based on continuous innovation and quality assurance. The company’s efforts in seeking clinical validation and integrating regulatory feedback highlight their operational expertise in transforming scientific discoveries into reliable therapeutic applications.

Why Investors and Analysts Watch Organogenesis

Investors and market analysts recognize Organogenesis not only for its diverse product lineup but also for its strong foundation rooted in regenerative medicine expertise. The company’s operational strategies, which blend scientific research with advanced manufacturing, serve as a model of precision and innovation in a competitive healthcare environment. Detailed insights into their product efficacy, market positioning, and tailored solutions for unmet clinical needs provide a clear window into the operational dynamics and the strategic value proposition of Organogenesis Holdings Inc.

Conclusion

The comprehensive approach of Organogenesis in addressing advanced wound care and surgical challenges is supported by decades of applied research in regenerative medicine. By focusing on bioactive and acellular biomaterials, the company continues to underpin its reputation as a trusted innovator, providing diversified yet focused solutions that cater to a wide array of clinical needs. The structured integration of scientific research, clinical trials, and manufacturing excellence makes Organogenesis an informative case study in modern patient care and biomedical innovation.

Rhea-AI Summary

Organogenesis Holdings (Nasdaq: ORGO) supports the U.S. Centers for Medicare & Medicaid Services' (CMS) decision to delay the implementation of local coverage determinations (LCDs) for skin substitute grafts and cellular tissue-based products (CTP) used in treating diabetic foot ulcers and venous leg ulcers.

The company endorses CMS's move to review coverage policies ensuring patient access to products with high-quality effectiveness evidence, including real-world evidence. CEO Gary S. Gillheeney Sr. recommends CMS implement an integrated coverage and payment policy to address rising Medicare costs while maintaining cost-effective patient care and innovation.

As a four-decade leader in regenerative medicine, Organogenesis pioneers bioengineered living cell products and manufactures advanced wound care therapies, with multiple technology platforms supporting clinically proven solutions that improve outcomes while reducing overall care costs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.64%
Tags
none
-
Rhea-AI Summary

Organogenesis Holdings (Nasdaq: ORGO), a regenerative medicine company specializing in Advanced Wound Care and Surgical and Sports Medicine markets, has scheduled its first quarter 2025 financial results announcement for May 8, 2025, after market close.

Management will conduct a conference call at 5:00 p.m. Eastern Time on the same day to discuss quarterly results and provide a corporate update, followed by a Q&A session. The event will be accessible via webcast through the company's investor relations website, where it will remain archived for approximately one year.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.88%
Tags
conferences earnings
-
Rhea-AI Summary

Organogenesis Holdings (NASDAQ: ORGO) reported strong Q4 2024 financial results with net revenue of $126.7 million, up 27% from Q4 2023. The company achieved Q4 net income of $7.7 million compared to a net loss of $0.6 million in Q4 2023.

For full-year 2024, revenue reached $482.0 million, an 11% increase from 2023, driven by Advanced Wound Care products (+12% to $453.6M) and Surgical & Sports Medicine products (+3% to $28.4M). The company ended 2024 with $136.2 million in cash and no outstanding debt.

For 2025 guidance, Organogenesis expects:

  • Net revenue between $480.0-$535.0 million
  • Net income between $9.5-$38.8 million
  • Adjusted EBITDA between $43.6-$83.2 million
The company also plans to submit the ReNu BLA by end of 2025, targeting knee OA treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
102.28%
Tags
Rhea-AI Summary

Organogenesis Holdings (Nasdaq: ORGO), a regenerative medicine company specializing in Advanced Wound Care and Surgical and Sports Medicine markets, has announced it will release its fourth quarter and fiscal year 2024 financial results after market close on February 27th, 2025.

Management will host a conference call at 5:00 p.m. Eastern Time on the same day to discuss quarterly and annual results, provide a corporate update, and conduct a Q&A session. The event will be accessible via live webcast through the company's investor relations website, where it will remain archived for approximately one year.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.06%
Tags
conferences earnings
-
Rhea-AI Summary

Organogenesis Holdings (Nasdaq: ORGO) announced plans to expand its manufacturing capacity through a long-term lease of a 122,000-square foot state-of-the-art biomanufacturing facility in Smithfield, Rhode Island. The regenerative medicine company, which focuses on Advanced Wound Care and Surgical and Sports Medicine markets, will maintain its existing operations across multiple locations including Massachusetts, Alabama, California, Florida, and Switzerland. The Rhode Island expansion is subject to state and local tax incentives.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.25%
Tags
none
-
News
Rhea-AI Summary

Organogenesis Holdings (Nasdaq: ORGO) welcomes the U.S. Centers for Medicare & Medicaid Services' decision on local coverage determination (LCD) for skin substitute grafts and cellular tissue-based products treating diabetic foot ulcers and venous leg ulcers. The LCD, effective February 12, 2025, is based on peer-reviewed clinical efficacy data. Organogenesis offers 4 products for diabetic foot ulcers, including NuShield, and 2 for venous leg ulcers. The company's NuShield product has been added to the list of covered products, marking a positive development for both the company and industry.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.62%
Tags
none
Rhea-AI Summary

Organogenesis Holdings (NASDAQ: ORGO) reported Q3 2024 financial results with net revenue of $115.2 million, up 6% from Q3 2023. Advanced Wound Care revenue increased 7% to $108.0 million, while Surgical & Sports Medicine revenue grew 1% to $7.2 million. Net income reached $12.3 million ($0.09 per share), up from $3.2 million in Q3 2023. Adjusted EBITDA was $13.4 million, down from $16.0 million year-over-year. The company updated its FY2024 guidance, expecting net revenue between $455-480 million, representing 5-11% growth, with projected net loss between $12.3-0.6 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
28.41%
Tags
-
Rhea-AI Summary

Organogenesis Holdings (Nasdaq: ORGO) has secured a $130 million private placement through the sale of Series A Convertible Preferred Stock to Avista Healthcare Partners. The net proceeds will fund strategic growth initiatives, including operating activities, clinical development, working capital, and debt repayment. $23.5 million will be used to repurchase 7.4 million shares of common stock from certain directors. The Preferred Stock is convertible into common stock at $3.79 per share, a 20% premium to recent trading. Investors will receive an 8% annual dividend, and Garrett Lustig from Avista joins the Board of Directors.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
28.41%
Tags
private placement
-
Rhea-AI Summary

Organogenesis Holdings (ORGO) announced positive interim analysis results from its second Phase 3 clinical trial of ReNu for knee osteoarthritis treatment. The analysis, covering 50% of 474 planned patients with moderate to severe knee OA, focused on the 6-month primary endpoint. The independent Data Monitoring Committee recommended proceeding without modifications or sample size increases, confirming favorable results and consistent safety profile. The fully enrolled 594-patient trial is evaluating ReNu versus saline control through intra-articular injection, with the primary endpoint measuring knee pain reduction using the WOMAC pain scale. Knee OA affects nearly 31.1 million Americans, projected to reach 34.4 million by 2027.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.43%
Tags
Rhea-AI Summary

Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company, has announced that it will report its third quarter fiscal year 2024 financial results after the market closes on Tuesday, November 12th, 2024. The company will host a conference call at 5:00 p.m. Eastern Time on the same day to discuss the quarterly results and provide a corporate update, followed by a question and answer session.

Interested parties can access the live webcast through the company's website at investors.organogenesis.com or via a provided link. A teleconference option is also available. The webcast will be archived on the company's website for approximately one year after the event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.72%
Tags
conferences earnings

FAQ

What is the current stock price of Organogenesis Hldgs (ORGO)?

The current stock price of Organogenesis Hldgs (ORGO) is $4.45 as of April 23, 2025.

What is the market cap of Organogenesis Hldgs (ORGO)?

The market cap of Organogenesis Hldgs (ORGO) is approximately 547.9M.

What is Organogenesis Holdings Inc?

Organogenesis Holdings Inc is a regenerative medicine company that develops, manufactures, and commercializes products for advanced wound care, surgical, and sports medicine markets.

Which markets does the company serve?

The company primarily serves the advanced wound care, surgical biologics, and sports medicine markets, addressing complex tissue repair and regeneration needs.

What types of products does Organogenesis offer?

Organogenesis offers a diverse portfolio of bioactive and acellular biomaterials, including skin substitutes, reinforcement matrices, and surgical barriers designed to support tissue repair.

How does Organogenesis ensure the quality of its products?

The company adheres to rigorous clinical evaluation and regulatory standards, integrating advanced research with scalable manufacturing processes to ensure high-quality and safe products.

What is the core focus of Organogenesis in regenerative medicine?

Organogenesis is dedicated to leveraging regenerative technologies to promote tissue repair and wound healing, providing innovative solutions across multiple clinical settings.

How is Organogenesis positioned within the healthcare industry?

Organogenesis is recognized for its technical expertise and comprehensive approach to regenerative medicine, making it a reputable and trusted entity in advanced wound care and surgical therapeutics.

How does the company integrate clinical research into its product development?

The company employs robust clinical trials and transparent data-driven methodologies to validate the efficacy and safety of its regenerative products, ensuring they meet stringent regulatory standards.
Organogenesis Hldgs Inc

Nasdaq:ORGO

ORGO Rankings

ORGO Stock Data

547.90M
67.47M
46.66%
49.76%
6.8%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States
CANTON